oscar health inc - OSCR
OSCR
Close Chg Chg %
32.14 1.33 4.14%
Closed Market
33.47
+1.33 (4.14%)
Volume: 4.25M
Last Updated:
Nov 10, 2026, 3:59 PM EDT
Company Overview: oscar health inc - OSCR
OSCR Key Data
| Open $32.47 | Day Range 32.26 - 33.75 |
| 52 Week Range 10.69 - 38.50 | Market Cap $9.46B |
| Shares Outstanding 308.65M | Public Float 253.30M |
| Beta 2.57 | Rev. Per Employee N/A |
| P/E Ratio 12.87 | EPS $2.77 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 5.61M |
OSCR Performance
| 1 Week | 4.86% | ||
| 1 Month | -3.69% | ||
| 3 Months | -1.89% | ||
| 1 Year | 131.56% | ||
| 5 Years | 163.88% |
OSCR Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
13
Full Ratings ➔
An error occurred while fetching the data.
An error occurred while fetching the data.
Snapshot
| Average Recommendation | HOLD | Average Target Price | 36.273 | |
| Number of Ratings | 13 | Current Quarters Estimate | -1.085 | |
| FY Report Date | 12 / 2026 | Current Year's Estimate | 2.351 | |
| Last Quarter’s Earnings | 0.49 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.69 | Next Fiscal Year Estimate | 2.60 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 11 | 7 | 10 | 11 |
| Mean Estimate | -1.08 | 2.30 | 2.35 | 2.60 |
| High Estimates | -0.95 | 2.76 | 2.70 | 3.28 |
| Low Estimate | -1.23 | 1.81 | 1.80 | 2.00 |
| Coefficient of Variance | -9.72 | 13.11 | 14.56 | 16.06 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 2 | 2 |
| OVERWEIGHT | 3 | 3 | 2 |
| HOLD | 7 | 7 | 7 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 0 | 0 | 0 |
| MEAN | Hold | Hold | Hold |
SEC Filings for Oscar Health Inc - OSCR
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Oscar Health Inc - OSCR
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Oct 14, 2026 | Siddhartha Sankaran Director | 3,533 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 14, 2026 | David Alexander Plouffe Director | 8,176 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 14, 2026 | William J. Gassen Director | 7,769 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 14, 2026 | Jeffery H. Boyd Director | 69,858 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 8, 2026 | Mark T. Bertolini Chief Executive Officer; Director | 10,196,877 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 8, 2026 | Mark T. Bertolini Chief Executive Officer; Director | 9,196,876 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $11.92 per share | 109,626,761.92 |
| Apr 8, 2026 | Mark T. Bertolini Chief Executive Officer; Director | 10,196,876 | Open market or private purchase of non-derivative security Non-derivative transaction at $11.92 per share | 121,546,761.92 |
| Apr 8, 2026 | Mark T. Bertolini Chief Executive Officer; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |